Jacek Stanislaw Malyszko

Dr. Jacek Stanislaw Malyszko


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BBBartłomiej Borawski
Bartłomiej Borawski
JMJacek Stanislaw Malyszko
Jacek Stanislaw Malyszko
MKMarlena Kwiatkowska
Marlena Kwiatkowska
Jolanta MałyszkoJolanta Małyszko
Jolanta Małyszko
Chronic kidney disease (CKD) is one of the fastest-growing major causes of death internationally. Better treatment of CKD and its complications is crucial to reverse this negative trend. Anemia is a frequent complication of CKD and is associated with unfavorable clinical outcomes. It is a devastating complication of progressive kidney disease, that negatively affects also the quality of life. The prevalence of anemia increases in parallel with CKD progression. The aim of this review is to summarize the current knowledge on therapy of renal anemia. Iron therapy, blood transfusions, and erythropoietin stimulating agents are still the mainstay of renal anemia treatment. There are several novel agents on the horizon that might provide therapeutic opportunities in CKD. The potential therapeutic options target the hepcidin–ferroportin axis, which is the master regulator of iron homeostasis, and the BMP-SMAD pathway, which regulates hepcidin expression in the liver. An inhibition of prolyl hydroxylase is a new therapeutic option becoming available for the treatment of anemia in CKD patients. This new class of drugs stimulates the synthesis of endogenous erythropoietin and increases iron availability. We also summarized the effects of prolyl hydroxylase inhibitors on iron parameters, including hepcidin, as their action on the hematological parameters. They could be of particular interest in the out-patient population with CKD and patients with ESA hyporesponsiveness. However, current knowledge is limited and still awaits clinical validation. One should be aware of the potential risks and benefits of novel, sophisticated therapies.

1 January 2003 in Transplant International
Verified
Journal Article
Closed access
PDF file
Jolanta MałyszkoJolanta Małyszko
Jolanta Małyszko
JMJacek Stanislaw Malyszko
Jacek Stanislaw Malyszko
MMMichal Mysliwiec
Michal Mysliwiec

2 February 2005 in Transplant International
Verified
Journal Article
Open access
PDF file
Jolanta MałyszkoJolanta Małyszko
Jolanta Małyszko
JMJacek Stanislaw Malyszko
Jacek Stanislaw Malyszko
Tomasz HryszkoTomasz Hryszko
Tomasz Hryszko
SBSzymon Brzosko
Szymon Brzosko
ULUrszula Lebkowska
Urszula Lebkowska
MMMichal Mysliwiec
Michal Mysliwiec
Cardiovascular disease (CVD) is the main cause of mortality and morbidity among kidney transplant recipients (Tx). Intima-media thickness (IMT) of the common carotid artery is related to CVD. Hemostatic disturbances may contribute to the CVD pathogenesis in Tx. The aim of the study was to evaluate some hemostatic factors in Tx with and without coronary artery disease (CAD) and their correlations with IMT. Patients with CAD were significantly older, with thicker IMT, lower plasmin–antiplasmin complexes (PAP), higher fibrinogen, cholesterol, triglycerides, Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity, prolonged euglobulin clot lysis time when compared to those without CAD. Kidney transplant recipients have higher mean blood pressure, serum lipids, fibrinogen, TAFI antigen, TAFI activity, markers of coagulation and fibrinolysis, thicker IMT and lower PAP relative to healthy volunteers. In univariate analysis, IMT correlated significantly with age, time on dialysis prior to transplantation, PAP, fibrinogen, hematocrit, body mass index (BMI). Multiple regression analysis showed that only age, hematocrit, PAP, and time on dialysis prior to transplantation were positive independent predictors of IMT. Hypofibrinolysis may contribute to the arterial remodeling in Tx. Dialysis therapy before transplantation makes detrimental changes in arterial vasculature.

1 March 2006 in Journal Of Nephrology
Verified
Journal Article
Closed access
JMJacek Stanislaw Malyszko
Jacek Stanislaw Malyszko
Jolanta MałyszkoJolanta Małyszko
Jolanta Małyszko
Tomasz HryszkoTomasz Hryszko
Tomasz Hryszko
PKPiotr Koz´mInski
Piotr Koz´mInski
KPKrystyna Pawlak
Krystyna Pawlak
MMMichal Mysliwiec
Michal Mysliwiec
Background: The purpose of the study was to assess whether renal replacement therapy (RRT) in the form of hemodialysis (HD) or hemodiafiltration (HDF) affects hemostasis and endothelial function in patients with end-stage renal failure (ESRF). Patients and methods: Thirty-five hemodialyzed patients and 14 HDF patients were evaluated regarding hemostatic parameters, serum lipids and endothelial cell injury markers. Results: HD patients did not differ significantly in regard to serum lipids, complete blood count, hemostasis, and dialysis adequacy as measured by Kt/V when compared to HDF patients. Only the markers of endothelial cell injury thrombomodulin and von Willebrand factor were significantly higher in HD when compared to HDF. Conclusions: Patients on HD showed evidence of a higher degree of endothelial dysfunction than HDF patients. HDF seems to ameliorate endothelial dysfunction in comparison with HD. Therefore, hemostatic abnormalities in ESRF might be affected to some extent by the choice of RRT.

2 January 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BSBartosz Symonides
Bartosz Symonides
MKMarlena Kwiatkowska-Stawiarczyk
Marlena Kwiatkowska-Stawiarczyk
JLJacek Krzysztof Lewandowski
Jacek Krzysztof Lewandowski
JMJacek Stanislaw Malyszko
Jacek Stanislaw Malyszko
Jolanta MałyszkoJolanta Małyszko
Jolanta Małyszko
Hypertension in chronic kidney disease patients is very common. The definition of resistant hypertension in the general population is as follows: uncontrolled blood pressure (BP) on three or more hypotensive agents in adequate doses, or when patients are on four or more hypotensive agent categories irrespective of the BP control, with diuretics included in the therapy. However, these resistant hypertension definitions do not apply to the setting of end-stage kidney disease. True resistant hypertension is diagnosed when adherence to treatment and uncontrolled values of BP by ambulatory blood pressure measurement or home blood pressure measurement are confirmed. Due to these limitations, apparent treatment-resistant hypertension (ATRH) is now defined as an uncontrolled blood pressure on three or more antihypertensive medication classes or the introduction and use of four or more medications regardless of blood pressure level. Concerning dialysis patients, data are very limited on hypertension, its epidemiology, and the prevalence of apparent treatment-resistant hypertension in peritoneal dialysis. In this review, therefore, we discuss the hypertension definitions, targets of the therapy in patients on peritoneal dialyses, and their biases and limitations. We present the pathophysiology, diagnosis, and management of high blood pressure in the peritoneally dialyzed population together with published data on the apparent treatment-resistant hypertension prevalence in this population. Peritoneally dialyzed patients represent a unique population of dialyzed subjects; therefore, studies should be conducted on a larger population with a higher quality of drug adherence and target blood pressure values. The definition of resistant hypertension and apparent resistant hypertension in this group should be redefined, which should also consider residual kidney function in relation to both subclinical and clinical endpoints.

Verified
Journal Article
Open access
PDF file
DKDana Kendzia
Dana Kendzia
FLFederica Lima
Federica Lima
JZJacek Piotr Zawierucha
Jacek Piotr Zawierucha
EBEllen Busink
Ellen Busink
CAChristian Apel
Christian Apel
Jolanta MałyszkoJolanta Małyszko
Jolanta Małyszko
Introduction: Home dialysis in Poland is restricted to the peritoneal dialysis (PD) modality, with the majority of dialysis patients treated using in-centre haemodialysis (ICHD). Home haemodialysis (HHD) is an additional home therapy to PD and provides an attractive alternative to ICHD that combines dialysis with social distancing; eliminates transportation needs; and offers clinical, economic, and quality of life benefits. However, HHD is not currently provided in Poland. This review was performed to provide an overview of the main barriers to the introduction of a HHD programme in Poland. Main findings: The main high-level barrier to introducing HHD in Poland is the absence of specific health legislation required for clinician prescribing of HHD. Other barriers to overcome include clear definition of reimbursement, patient training and education (including infrastructure and experienced personnel), organisation of logistics, and management of complications. Partnering with a large care network for HHD represents an alternative option to payers for the provision of a new HHD service. This may reduce some of the barriers which need to be overcome when compared with the creation of a new HHD service and its supporting network due to the pre-existing infrastructure, processes, and staff of a large care network. Conclusions: Provision of HHD is not solely about the provision of home treatment, but also the organisation and definition of a range of support services that are required to deliver the service. HHD should be viewed as an additional, complementary option to existing dialysis modalities which enables choice of modality best suited to a patient’s needs.